UBS Maintains Buy on Dentsply Sirona, Lowers Price Target to $13
Benzinga Newsdesk 22 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
UBS analyst Kevin Caliendo maintains Dentsply Sirona (NASDAQ:XRAY) with a Buy and lowers the price target from $17 to $13.
UBS analyst Kevin Caliendo maintains Dentsply Sirona (NASDAQ:XRAY) with a Buy and lowers the price target from $17 to $13.
